ID
25469
Beschrijving
Study ID: 101468/166 Clinical Study ID: SKF-101468/166 Study Title: A Phase II, randomised, double-blind, active-controlled, dose-escalation study to determine the maximum well-tolerated starting dose of a new formulation of ropinirole in Parkinson's Disease patients not receiving other dopaminergic therapies Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 2 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: requip Study Indication: Parkinson Disease
Trefwoorden
Versies (2)
- 31-08-17 31-08-17 -
- 04-09-17 04-09-17 -
Geüploaded op
4 september 2017
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY-NC 3.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
visit 2 & 3-4 Patient's Daily Diary starting dose of ropinirole Parkinson's Disease 101468/166
visit 2 & 3-4 Patient's Daily Diary starting dose of ropinirole Parkinson's Disease 101468/166
Beschrijving
HEALTH RELATED EVENTS
Alias
- UMLS CUI-1
- C1562065
Beschrijving
event
Datatype
text
Alias
- UMLS CUI [1]
- C0441471
Beschrijving
start date and time
Datatype
datetime
Alias
- UMLS CUI [1]
- C0808070
- UMLS CUI [2]
- C1301880
Beschrijving
stop date and time
Datatype
datetime
Alias
- UMLS CUI [1]
- C0806020
- UMLS CUI [2]
- C1522314
Beschrijving
Only tick the box, if the event is still going on.
Datatype
text
Alias
- UMLS CUI [1]
- C0549178
Similar models
visit 2 & 3-4 Patient's Daily Diary starting dose of ropinirole Parkinson's Disease 101468/166
C0376660 (UMLS CUI [1,2])
C1522634 (UMLS CUI [1,2])
C1301880 (UMLS CUI [2])
C1522314 (UMLS CUI [2])